ArticleNeurology. Clinical practice2025
The Leeds Motor Neuron Disease Percutaneous Endoscopic Gastrostomy Pathway: Improving Clinical Outcomes and Experience in a UK Center.
Article in Neurology. Clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: We outline a quality improvement project on the development of a percutaneous endoscopic gastrostomy (PEG) pathway for patients with motor neuron disease (MND) in a single UK specialist hospital. Methods: Data were collected for 110 patients with MND from 2011 to 2014 before the development of the MND PEG pathway in 2015 and thereafter from 2018 to 2022. Results: Time from MND diagnosis to PEG discussion, time from discussion to referral, and time from referral to PEG insertion were shorter under the new pathway which is of clinical significance, although not statistically significant. The infection rate post-PEG insertion was significantly reduced. Financial savings were made due to the reduced length of stay and no intensive care unit admissions post-PEG insertion. Discussion: Our PEG pathway standardized and streamlined services resulting in reduction of total time taken in the pathway: from initial discussion to decision and procedure. It also reduced post-PEG infections and overall costs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.